MedTrace Logo

Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy

NCT07390864 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-02-05

No results posted yet for this study

Summary

The goal of this randomized clinical trial is to determine whether intramyometrial ergometrine injection or intramyometrial carbetocin injection is more effective in reducing blood loss during and after abdominal myomectomy in women undergoing surgery for symptomatic uterine fibroids.

The main questions it aims to answer are:

Does intramyometrial ergometrine reduce intraoperative and postoperative blood loss during abdominal myomectomy?

Does intramyometrial carbetocin reduce intraoperative and postoperative blood loss during abdominal myomectomy?

Is there a difference between the two drugs in the need for blood transfusion and postoperative hemoglobin drop?

Researchers will compare intramyometrial ergometrine injection with intramyometrial carbetocin injection to see which intervention is more effective in controlling surgical bleeding and improving surgical outcomes.

Participants will:

Undergo abdominal myomectomy for uterine fibroids

Receive either intramyometrial ergometrine or intramyometrial carbetocin during surgery

Be monitored for intraoperative blood loss, postoperative blood loss, hemoglobin changes, and need for blood transfusion

Conditions

  • Myoma;Uterus

Interventions

DRUG

Methylergometrine (Intramyometrial Injection)

Methylergometrine maleate is administered as an intramyometrial injection diluted in normal saline and injected circumferentially around the myoma before uterine incision during abdominal myomectomy to induce sustained uterine contraction and reduce surgical blood loss.

DRUG

Carbetocin (Intramyometrial Injection)

Carbetocin is administered as an intramyometrial injection diluted in normal saline and injected circumferentially around the myoma before uterine incision during abdominal myomectomy to promote sustained uterine contraction and reduce intraoperative and postoperative blood loss.

Sponsors & Collaborators

  • Kafrelsheikh University

    collaborator OTHER

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
48 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-18
Primary Completion
2026-07-30
Completion
2026-08-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07390864 on ClinicalTrials.gov